Savara can be a scientific-stage biopharmaceutical company creating treatment options for scarce respiratory health conditions. Its lead solution prospect is an immunostimulator called molgramostim. Molgramostim is in stage three scientific trials to treat autoimmune pulmonary alveolar proteinosis, or aPAP. Musk appointed Linda Yaccarino CEO of X Corp., the successor https://financefeeds.com/archax-enters-us-via-globacap-pmi-acquisition/